Cenya Imaging B.V.


Cenya Imaging is developing a clinical stage contrast agent to label, track and quantify cell therapies in humans over extended periods of time. Cenya’s BEAds for CONtrast enhancement (BEACONs) offer contrast for 19F-MRI, ultrasound and photoacoustic imaging, and can be further modified for PET, SPECT and CT imaging. Extensive ex vivo and in vivo data demonstrate that BEACONs readily label a wide range of primary cell types without impacting function, and are safe in vivo. BEACONs are approved for use in a first in human trial to track a dendritic cell therapy.